Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Thazha P. Prakash"'
Autor:
Tatyana Gurlo, Thazha P. Prakash, Zhongying Wang, Maani Archang, Lina Pei, Madeline Rosenberger, Elaine Pirie, Richard G. Lee, Peter C. Butler
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2023)
Insulin resistance is the major risk factor for Type 2 diabetes (T2D). In vulnerable individuals, insulin resistance induces a progressive loss of insulin secretion with islet pathology revealing a partial deficit of beta cells and islet amyloid deri
Externí odkaz:
https://doaj.org/article/bf1ee849ed3745778fd1c233039aded4
Publikováno v:
Molecules, Vol 24, Iss 2, p 225 (2019)
We recently reported that (E)-5′-vinylphosphonate (5′-VP) is a metabolically-stable phosphate mimic for siRNA and demonstrated that 5′-VP improves the potency of the fully modified siRNAs in vivo. Here, we report an alternative synthesis of 5
Externí odkaz:
https://doaj.org/article/bad97e013ffb478cbbb8d1b4f1730a83
Autor:
Carol Kuo, Mehran Nikan, Steve T. Yeh, Alfred E. Chappell, Michael Tanowitz, Punit P. Seth, Thazha P. Prakash, Adam E. Mullick
Publikováno v:
Nucleic Acid Therapeutics. 32:300-311
We evaluated the potential of AGTR1, the principal receptor for angiotensin II (Ang II) and a member of the G protein-coupled receptor family, for targeted delivery of antisense oligonucleotides (ASOs) in cells and tissues with abundant AGTR1 express
Autor:
Yanjie Li, Jixue Li, Jun Wang, Siyuan Zhang, Keith Giles, Thazha P Prakash, Frank Rigo, Jill S Napierala, Marek Napierala
Publikováno v:
Human Molecular Genetics. 31:3539-3557
Frataxin deficiency in Friedreich’s ataxia results from transcriptional downregulation of the FXN gene caused by expansion of the intronic trinucleotide guanine-adenine-adenine (GAA) repeats. We used multiple transcriptomic approaches to determine
Autor:
Svenja Wiechmann, Tufan Gökirmak, Punit P. Seth, Michael Tanowitz, Mehran Nikan, Thazha P. Prakash
Publikováno v:
Trends in Pharmacological Sciences. 42:588-604
Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and ov
Autor:
Cheryl L De Hoyos, Thazha P. Prakash, Xue-hai Liang, Wen Shen, Hans Gaus, Stanley T. Crooke, Jinghua Yu, Andres Berdeja, Punit P. Seth
Publikováno v:
ACS Med Chem Lett
[Image: see text] Site-specific incorporation of 2′-modifications and neutral linkages in the deoxynucleotide gap region of toxic phosphorothioate (PS) gapmer ASOs can enhance therapeutic index and safety. In this manuscript, we determined the effe
Autor:
Punit P. Seth, Johan Broddefalk, Patrik U. Andersson, Johan Meuller, Michael E. Østergaard, Thazha P. Prakash, Linda Sundström, Leonardo De Maria, Wuxia Fu, Ahlke Hayen, David Janzén, Carina Ämmälä, Eric Valeur, Laurent Knerr, Maria Ölwegård-Halvarsson, Richard G. Lee, Shalini Andersson, William J. Drury, Elaine Pirie, Mehran Nikan, Rasmus Jansson-Löfmark
Publikováno v:
Journal of the American Chemical Society. 143:3416-3429
The extra hepatic delivery of antisense oligonucleotides (ASOs) remains a challenge and hampers the widespread application of this powerful class of therapeutic agents. In that regard, pancreatic beta cells are a particularly attractive but challengi
Autor:
Xue-hai Liang, Cheryl L De Hoyos, Punit P. Seth, Stanley T. Crooke, Graeme C Freestone, Michael E Ǿstergaard, Audrey Low, Guillermo Vasquez, Jinghua Yu, Eric E. Swayze, Michael T. Migawa, W. Brad Wan, Thazha P. Prakash
Publikováno v:
Nucleic Acids Research
We recently showed that site-specific incorporation of 2′-modifications or neutral linkages in the oligo-deoxynucleotide gap region of toxic phosphorothioate (PS) gapmer ASOs can enhance therapeutic index and safety. In this manuscript, we determin
Autor:
Rosie Z Yu, Mark J Graham, Noah Post, Stan Riney, Thomas Zanardi, Shannon Hall, Jennifer Burkey, Colby S Shemesh, Thazha P Prakash, Punit P Seth, Eric E Swayze, Richard S Geary, Yanfeng Wang, Scott Henry
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency via receptor-mediated uptake. In the present study, the in vivo pharmacology of a 2′-O-(2-methoxyethyl)-modified ASO conjugated
Externí odkaz:
https://doaj.org/article/2b26807b841244429f7ffc38c01b9c47
Autor:
Colby S Shemesh, Rosie Z Yu, Hans J Gaus, Sarah Greenlee, Noah Post, Karsten Schmidt, Michael T Migawa, Punit P Seth, Thomas A Zanardi, Thazha P Prakash, Eric E Swayze, Scott P Henry, Yanfeng Wang
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
Triantennary N-acetyl galactosamine (GalNAc3) is a high-affinity ligand for hepatocyte-specific asialoglycoprotein receptors. Conjugation with GalNAc3 via a trishexylamino (THA)-C6 cluster significantly enhances antisense oligonucleotide (ASO) potenc
Externí odkaz:
https://doaj.org/article/1de8c3f8738147bdba5db5c61c7a342f